HC Wainwright Weighs in on ArriVent BioPharma, Inc.’s Q1 2024 Earnings (NASDAQ:AVBP)

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Equities researchers at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of ArriVent BioPharma in a report released on Tuesday, April 30th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.25) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.11) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2024 earnings at ($0.64) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($3.03) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.09) EPS.

Other research analysts have also issued reports about the stock. Citigroup started coverage on shares of ArriVent BioPharma in a report on Tuesday, February 20th. They issued a “buy” rating and a $30.00 target price on the stock. The Goldman Sachs Group started coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Jefferies Financial Group started coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $35.00 price objective on the stock.

ArriVent BioPharma Stock Up 2.6 %

NASDAQ AVBP opened at $17.23 on Thursday. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $25.95. The business has a fifty day moving average of $18.02.

Institutional Trading of ArriVent BioPharma

An institutional investor recently bought a new position in ArriVent BioPharma stock. BNP Paribas Financial Markets acquired a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,659 shares of the company’s stock, valued at approximately $83,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.